![David A. Lowin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David A. Lowin
Profile
David A.
Lowin is associated with two companies, Kanyos Bio, Inc. and Anokion SA. He is the founder of Kanyos Bio, Inc. which was founded in 2015.
At Anokion SA, he held the title of Chief Legal Officer and was the founder of the company which was founded in 2012.
Former positions of David A. Lowin
Companies | Position | End |
---|---|---|
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Founder | - |
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Founder | - |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- David A. Lowin